NCT01540409View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 27, 2012

Primary Completion Date

April 15, 2016

Study Completion Date

August 16, 2017

Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
DRUG

AVI-4658 (Eteplirsen)

Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.

Trial Locations (11)

13088

Summerwood Pediatrics/Infusacare Medical Services, Liverpool

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

23510

Children's Specialty Group, Pediatric Neurology, Norfolk

28203

Levine Children's Hospital, Charlotte

32610

University of Florida Clinical Research Center, Gainesville

43205

Nationwide Children's Hospital, Columbus

54020

Osceola Medical Center, Osceola

60612

Rush University Medical Center, Chicago

63110

Washington University Medical School, St Louis

90806

Miller Children's Hospital, Long Beach

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Sarepta Therapeutics, Inc.

INDUSTRY

NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter